Literature DB >> 18513799

Local secretion/shedding of tumor-derived CD83 molecules as a novel tumor escape mechanism.

R B Baleeiro, J A M Barbuto.   

Abstract

CD83, a characteristic marker of activated dendritic cells, is also expressed by tumor cell lines from various origins and by primary lung cancers. Here, we show that CD83+ tumor cells (from a primary lung cancer and from an established breast cancer cell line) release in their culture supernatants a soluble factor that is able to block, in a dose-dependent manner, CD4+ and CD8+ T cell proliferative responses to allogeneic dendritic cells. This factor was removed from the medium by incubation in anti-CD83 covered plates, indicating that it could be one of the known soluble forms of the CD83 molecule, released in the medium by the cultured tumor cells. This phenomenon, happening in vivo, in the tumor microenvironment, could affect profoundly anti-tumor immune responses and should, therefore, be considered in immunotherapeutic approaches to cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18513799     DOI: 10.1016/j.molimm.2008.04.005

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

1.  Soluble CD83 Inhibits T Cell Activation by Binding to the TLR4/MD-2 Complex on CD14+ Monocytes.

Authors:  Joe M Horvatinovich; Elizabeth W Grogan; Marcus Norris; Alexander Steinkasserer; Henrique Lemos; Andrew L Mellor; Irina Y Tcherepanova; Charles A Nicolette; Mark A DeBenedette
Journal:  J Immunol       Date:  2017-02-13       Impact factor: 5.422

2.  Evaluation of Soluble CD90: Potential for Diagnostic Significance in Endometriosis Patients.

Authors:  Ivan M Bochev; Iliya I Karagyozov; Nadya M Magunska; Vesselina S Koleva; Ivan V Krumov; Elena S Puncheva; Georgi P Boyadzhiev; Kameliya Vinketova; Milena S Mourdjeva; Tsvetelina P Oreshkova
Journal:  Dis Markers       Date:  2022-06-20       Impact factor: 3.464

3.  Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody.

Authors:  Ziduo Li; Edward Abadir; Kenneth Lee; Candice Clarke; Christian E Bryant; Wendy Cooper; Geoffrey Pietersz; James Favaloro; Pablo A Silveira; Derek Nj Hart; Xinsheng Ju; Georgina J Clark
Journal:  Clin Transl Immunology       Date:  2020-07-15

4.  PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer.

Authors:  C A Crane; A Panner; J C Murray; S P Wilson; H Xu; L Chen; J P Simko; F M Waldman; R O Pieper; A T Parsa
Journal:  Oncogene       Date:  2008-10-13       Impact factor: 9.867

5.  Essential role of the linear ubiquitin chain assembly complex and TAK1 kinase in A20 mutant Hodgkin lymphoma.

Authors:  Zhihui Song; Wei Wei; Wenming Xiao; Essel D Al-Saleem; Reza Nejati; Liqi Chen; Jiejing Yin; Joseph Fabrizio; Michael N Petrus; Thomas A Waldmann; Yibin Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-02       Impact factor: 12.779

Review 6.  SheddomeDB: the ectodomain shedding database for membrane-bound shed markers.

Authors:  Wei-Sheng Tien; Jun-Hong Chen; Kun-Pin Wu
Journal:  BMC Bioinformatics       Date:  2017-03-14       Impact factor: 3.169

7.  Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy.

Authors:  Carol M Amato; Jennifer D Hintzsche; Keith Wells; Allison Applegate; Nicholas T Gorden; Victoria M Vorwald; Richard P Tobin; Kelsey Nassar; Yiqun G Shellman; Jihye Kim; Theresa M Medina; Matthew Rioth; Karl D Lewis; Martin D McCarter; Rene Gonzalez; Aik-Choon Tan; William A Robinson
Journal:  Cancers (Basel)       Date:  2020-07-17       Impact factor: 6.639

Review 8.  The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.

Authors:  Barbara Seliger; Chiara Massa
Journal:  Front Immunol       Date:  2013-12-02       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.